Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Nivolumab in Advanced SCLC
NCT03662074Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, nivolumab in Small Cell Lung Cancer (SCLC), sponsored by Wake Forest University Health Sciences. Started Nov 2018; status: terminated.
02
Drugs
gemcitabinenivolumab
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT03662074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662074.